Supplementary Figure S1 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Article Swipe
Matteo Dugo
,
Chiun‐Sheng Huang
,
Daniel Egle
,
Begoña Bermejo
,
C. Zamagni
,
Robert S. Seitz
,
Tyler J. Nielsen
,
Marc Thill
,
Antonio Antón
,
Stefania Russo
,
Eva Ciruelos
,
Brock L. Schweitzer
,
Douglas Teller Ross
,
Barbara Galbardi
,
Richard Greil
,
Semiglazov Vf
,
Balázs Győrffy
,
Marco Colleoni
,
Catherine M. Kelly
,
Gabriella Mariani
,
Lucia Del Mastro
,
Olivia Blasi
,
Maurizio Callari
,
Lajos Pusztai
,
Pinuccia Valagussa
,
Giuseppe Viale
,
Luca Gianni
,
Giampaolo Bianchini
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1158/1078-0432.27434278
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1158/1078-0432.27434278
Supplementary Figure 1. Quality control of NeoTRIP RNA-Seq data. Boxplots showing the distribution of read depth of targeted coding regions by arm and response status. Dots represent the read depth of single samples. The horizontal grey dashed line represents the cut-off of 40 million paired-end reads.
Related Topics
Concepts
Atezolizumab
Triple-negative breast cancer
Breast cancer
Oncology
Chemotherapy
Gene signature
Signature (topology)
Medicine
Cancer
Neoadjuvant therapy
Internal medicine
Gene
Cancer research
Biology
Immunotherapy
Genetics
Gene expression
Pembrolizumab
Mathematics
Geometry
Metadata
- Type
- preprint
- Language
- en
- Landing Page
- https://doi.org/10.1158/1078-0432.27434278
- https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S1_from_The_Immune-Related_27-Gene_Signature_DetermaIO_Predicts_Response_to_Neoadjuvant_Atezolizumab_plus_Chemotherapy_in_Triple-Negative_Breast_Cancer/27434278/1/files/50134564.pdf
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4403988497
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4403988497Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1158/1078-0432.27434278Digital Object Identifier
- Title
-
Supplementary Figure S1 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast CancerWork title
- Type
-
preprintOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-11-01Full publication date if available
- Authors
-
Matteo Dugo, Chiun‐Sheng Huang, Daniel Egle, Begoña Bermejo, C. Zamagni, Robert S. Seitz, Tyler J. Nielsen, Marc Thill, Antonio Antón, Stefania Russo, Eva Ciruelos, Brock L. Schweitzer, Douglas Teller Ross, Barbara Galbardi, Richard Greil, Semiglazov Vf, Balázs Győrffy, Marco Colleoni, Catherine M. Kelly, Gabriella Mariani, Lucia Del Mastro, Olivia Blasi, Maurizio Callari, Lajos Pusztai, Pinuccia Valagussa, Giuseppe Viale, Luca Gianni, Giampaolo BianchiniList of authors in order
- Landing page
-
https://doi.org/10.1158/1078-0432.27434278Publisher landing page
- PDF URL
-
https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S1_from_The_Immune-Related_27-Gene_Signature_DetermaIO_Predicts_Response_to_Neoadjuvant_Atezolizumab_plus_Chemotherapy_in_Triple-Negative_Breast_Cancer/27434278/1/files/50134564.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S1_from_The_Immune-Related_27-Gene_Signature_DetermaIO_Predicts_Response_to_Neoadjuvant_Atezolizumab_plus_Chemotherapy_in_Triple-Negative_Breast_Cancer/27434278/1/files/50134564.pdfDirect OA link when available
- Concepts
-
Atezolizumab, Triple-negative breast cancer, Breast cancer, Oncology, Chemotherapy, Gene signature, Signature (topology), Medicine, Cancer, Neoadjuvant therapy, Internal medicine, Gene, Cancer research, Biology, Immunotherapy, Genetics, Gene expression, Pembrolizumab, Mathematics, GeometryTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4403988497 |
|---|---|
| doi | https://doi.org/10.1158/1078-0432.27434278 |
| ids.doi | https://doi.org/10.1158/1078-0432.27434278 |
| ids.openalex | https://openalex.org/W4403988497 |
| fwci | 0.0 |
| type | preprint |
| title | Supplementary Figure S1 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10158 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9987999796867371 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2730 |
| topics[0].subfield.display_name | Oncology |
| topics[0].display_name | Cancer Immunotherapy and Biomarkers |
| topics[1].id | https://openalex.org/T10580 |
| topics[1].field.id | https://openalex.org/fields/24 |
| topics[1].field.display_name | Immunology and Microbiology |
| topics[1].score | 0.9815000295639038 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2403 |
| topics[1].subfield.display_name | Immunology |
| topics[1].display_name | Immunotherapy and Immune Responses |
| topics[2].id | https://openalex.org/T11491 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9710999727249146 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2730 |
| topics[2].subfield.display_name | Oncology |
| topics[2].display_name | CAR-T cell therapy research |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2775949291 |
| concepts[0].level | 5 |
| concepts[0].score | 0.9666438102722168 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q20707748 |
| concepts[0].display_name | Atezolizumab |
| concepts[1].id | https://openalex.org/C2780110267 |
| concepts[1].level | 4 |
| concepts[1].score | 0.8111699819564819 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q7843332 |
| concepts[1].display_name | Triple-negative breast cancer |
| concepts[2].id | https://openalex.org/C530470458 |
| concepts[2].level | 3 |
| concepts[2].score | 0.6684699058532715 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q128581 |
| concepts[2].display_name | Breast cancer |
| concepts[3].id | https://openalex.org/C143998085 |
| concepts[3].level | 1 |
| concepts[3].score | 0.565502405166626 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[3].display_name | Oncology |
| concepts[4].id | https://openalex.org/C2776694085 |
| concepts[4].level | 2 |
| concepts[4].score | 0.5076237916946411 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[4].display_name | Chemotherapy |
| concepts[5].id | https://openalex.org/C2779733811 |
| concepts[5].level | 4 |
| concepts[5].score | 0.49515214562416077 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q5531562 |
| concepts[5].display_name | Gene signature |
| concepts[6].id | https://openalex.org/C2779696439 |
| concepts[6].level | 2 |
| concepts[6].score | 0.44824251532554626 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q7512811 |
| concepts[6].display_name | Signature (topology) |
| concepts[7].id | https://openalex.org/C71924100 |
| concepts[7].level | 0 |
| concepts[7].score | 0.4455059766769409 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[7].display_name | Medicine |
| concepts[8].id | https://openalex.org/C121608353 |
| concepts[8].level | 2 |
| concepts[8].score | 0.4265788793563843 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[8].display_name | Cancer |
| concepts[9].id | https://openalex.org/C2778292576 |
| concepts[9].level | 4 |
| concepts[9].score | 0.41102105379104614 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q6991934 |
| concepts[9].display_name | Neoadjuvant therapy |
| concepts[10].id | https://openalex.org/C126322002 |
| concepts[10].level | 1 |
| concepts[10].score | 0.3969424366950989 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[10].display_name | Internal medicine |
| concepts[11].id | https://openalex.org/C104317684 |
| concepts[11].level | 2 |
| concepts[11].score | 0.38358405232429504 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q7187 |
| concepts[11].display_name | Gene |
| concepts[12].id | https://openalex.org/C502942594 |
| concepts[12].level | 1 |
| concepts[12].score | 0.32914531230926514 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[12].display_name | Cancer research |
| concepts[13].id | https://openalex.org/C86803240 |
| concepts[13].level | 0 |
| concepts[13].score | 0.23691996932029724 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[13].display_name | Biology |
| concepts[14].id | https://openalex.org/C2777701055 |
| concepts[14].level | 3 |
| concepts[14].score | 0.19189637899398804 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q1427096 |
| concepts[14].display_name | Immunotherapy |
| concepts[15].id | https://openalex.org/C54355233 |
| concepts[15].level | 1 |
| concepts[15].score | 0.1312372088432312 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q7162 |
| concepts[15].display_name | Genetics |
| concepts[16].id | https://openalex.org/C150194340 |
| concepts[16].level | 3 |
| concepts[16].score | 0.1250593066215515 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q26972 |
| concepts[16].display_name | Gene expression |
| concepts[17].id | https://openalex.org/C2780057760 |
| concepts[17].level | 4 |
| concepts[17].score | 0.0 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q13896859 |
| concepts[17].display_name | Pembrolizumab |
| concepts[18].id | https://openalex.org/C33923547 |
| concepts[18].level | 0 |
| concepts[18].score | 0.0 |
| concepts[18].wikidata | https://www.wikidata.org/wiki/Q395 |
| concepts[18].display_name | Mathematics |
| concepts[19].id | https://openalex.org/C2524010 |
| concepts[19].level | 1 |
| concepts[19].score | 0.0 |
| concepts[19].wikidata | https://www.wikidata.org/wiki/Q8087 |
| concepts[19].display_name | Geometry |
| keywords[0].id | https://openalex.org/keywords/atezolizumab |
| keywords[0].score | 0.9666438102722168 |
| keywords[0].display_name | Atezolizumab |
| keywords[1].id | https://openalex.org/keywords/triple-negative-breast-cancer |
| keywords[1].score | 0.8111699819564819 |
| keywords[1].display_name | Triple-negative breast cancer |
| keywords[2].id | https://openalex.org/keywords/breast-cancer |
| keywords[2].score | 0.6684699058532715 |
| keywords[2].display_name | Breast cancer |
| keywords[3].id | https://openalex.org/keywords/oncology |
| keywords[3].score | 0.565502405166626 |
| keywords[3].display_name | Oncology |
| keywords[4].id | https://openalex.org/keywords/chemotherapy |
| keywords[4].score | 0.5076237916946411 |
| keywords[4].display_name | Chemotherapy |
| keywords[5].id | https://openalex.org/keywords/gene-signature |
| keywords[5].score | 0.49515214562416077 |
| keywords[5].display_name | Gene signature |
| keywords[6].id | https://openalex.org/keywords/signature |
| keywords[6].score | 0.44824251532554626 |
| keywords[6].display_name | Signature (topology) |
| keywords[7].id | https://openalex.org/keywords/medicine |
| keywords[7].score | 0.4455059766769409 |
| keywords[7].display_name | Medicine |
| keywords[8].id | https://openalex.org/keywords/cancer |
| keywords[8].score | 0.4265788793563843 |
| keywords[8].display_name | Cancer |
| keywords[9].id | https://openalex.org/keywords/neoadjuvant-therapy |
| keywords[9].score | 0.41102105379104614 |
| keywords[9].display_name | Neoadjuvant therapy |
| keywords[10].id | https://openalex.org/keywords/internal-medicine |
| keywords[10].score | 0.3969424366950989 |
| keywords[10].display_name | Internal medicine |
| keywords[11].id | https://openalex.org/keywords/gene |
| keywords[11].score | 0.38358405232429504 |
| keywords[11].display_name | Gene |
| keywords[12].id | https://openalex.org/keywords/cancer-research |
| keywords[12].score | 0.32914531230926514 |
| keywords[12].display_name | Cancer research |
| keywords[13].id | https://openalex.org/keywords/biology |
| keywords[13].score | 0.23691996932029724 |
| keywords[13].display_name | Biology |
| keywords[14].id | https://openalex.org/keywords/immunotherapy |
| keywords[14].score | 0.19189637899398804 |
| keywords[14].display_name | Immunotherapy |
| keywords[15].id | https://openalex.org/keywords/genetics |
| keywords[15].score | 0.1312372088432312 |
| keywords[15].display_name | Genetics |
| keywords[16].id | https://openalex.org/keywords/gene-expression |
| keywords[16].score | 0.1250593066215515 |
| keywords[16].display_name | Gene expression |
| language | en |
| locations[0].id | doi:10.1158/1078-0432.27434278 |
| locations[0].is_oa | True |
| locations[0].source | |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S1_from_The_Immune-Related_27-Gene_Signature_DetermaIO_Predicts_Response_to_Neoadjuvant_Atezolizumab_plus_Chemotherapy_in_Triple-Negative_Breast_Cancer/27434278/1/files/50134564.pdf |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.1158/1078-0432.27434278 |
| locations[1].id | pmh:oai:figshare.com:article/27434278 |
| locations[1].is_oa | True |
| locations[1].source.id | https://openalex.org/S4306400572 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | OPAL (Open@LaTrobe) (La Trobe University) |
| locations[1].source.host_organization | https://openalex.org/I196829312 |
| locations[1].source.host_organization_name | La Trobe University |
| locations[1].source.host_organization_lineage | https://openalex.org/I196829312 |
| locations[1].license | cc-by |
| locations[1].pdf_url | |
| locations[1].version | submittedVersion |
| locations[1].raw_type | Text |
| locations[1].license_id | https://openalex.org/licenses/cc-by |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | |
| locations[1].landing_page_url | https://figshare.com/articles/journal_contribution/Supplementary_Figure_S1_from_The_Immune-Related_27-Gene_Signature_DetermaIO_Predicts_Response_to_Neoadjuvant_Atezolizumab_plus_Chemotherapy_in_Triple-Negative_Breast_Cancer/27434278 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5063636724 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-9786-2763 |
| authorships[0].author.display_name | Matteo Dugo |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Matteo Dugo |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5027981189 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-6557-211X |
| authorships[1].author.display_name | Chiun‐Sheng Huang |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Chiun-Sheng Huang |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5049254392 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-0283-8176 |
| authorships[2].author.display_name | Daniel Egle |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Daniel Egle |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5018922989 |
| authorships[3].author.orcid | https://orcid.org/0000-0001-7773-5994 |
| authorships[3].author.display_name | Begoña Bermejo |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Begoña Bermejo |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5021445195 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-7143-9091 |
| authorships[4].author.display_name | C. Zamagni |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Claudio Zamagni |
| authorships[4].is_corresponding | False |
| authorships[5].author.id | https://openalex.org/A5033135467 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-5806-2840 |
| authorships[5].author.display_name | Robert S. Seitz |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Robert S. Seitz |
| authorships[5].is_corresponding | False |
| authorships[6].author.id | https://openalex.org/A5050750573 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-9576-2838 |
| authorships[6].author.display_name | Tyler J. Nielsen |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Tyler J. Nielsen |
| authorships[6].is_corresponding | False |
| authorships[7].author.id | https://openalex.org/A5055136263 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-8800-8044 |
| authorships[7].author.display_name | Marc Thill |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Marc Thill |
| authorships[7].is_corresponding | False |
| authorships[8].author.id | https://openalex.org/A5090790623 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-2802-6232 |
| authorships[8].author.display_name | Antonio Antón |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Antonio Antón-Torres |
| authorships[8].is_corresponding | False |
| authorships[9].author.id | https://openalex.org/A5048548720 |
| authorships[9].author.orcid | |
| authorships[9].author.display_name | Stefania Russo |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Stefania Russo |
| authorships[9].is_corresponding | False |
| authorships[10].author.id | https://openalex.org/A5077805370 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-2796-1042 |
| authorships[10].author.display_name | Eva Ciruelos |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Eva Maria Ciruelos |
| authorships[10].is_corresponding | False |
| authorships[11].author.id | https://openalex.org/A5010230522 |
| authorships[11].author.orcid | https://orcid.org/0000-0003-0178-5594 |
| authorships[11].author.display_name | Brock L. Schweitzer |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Brock L. Schweitzer |
| authorships[11].is_corresponding | False |
| authorships[12].author.id | https://openalex.org/A5008822450 |
| authorships[12].author.orcid | |
| authorships[12].author.display_name | Douglas Teller Ross |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Douglas T. Ross |
| authorships[12].is_corresponding | False |
| authorships[13].author.id | https://openalex.org/A5029069852 |
| authorships[13].author.orcid | https://orcid.org/0000-0003-1424-421X |
| authorships[13].author.display_name | Barbara Galbardi |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Barbara Galbardi |
| authorships[13].is_corresponding | False |
| authorships[14].author.id | https://openalex.org/A5039994927 |
| authorships[14].author.orcid | https://orcid.org/0000-0002-4462-3694 |
| authorships[14].author.display_name | Richard Greil |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Richard Greil |
| authorships[14].is_corresponding | False |
| authorships[15].author.id | https://openalex.org/A5068100907 |
| authorships[15].author.orcid | https://orcid.org/0000-0003-0077-9619 |
| authorships[15].author.display_name | Semiglazov Vf |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | Vladimir Semiglazov |
| authorships[15].is_corresponding | False |
| authorships[16].author.id | https://openalex.org/A5023340072 |
| authorships[16].author.orcid | |
| authorships[16].author.display_name | Balázs Győrffy |
| authorships[16].author_position | middle |
| authorships[16].raw_author_name | Balázs Gyorffy |
| authorships[16].is_corresponding | False |
| authorships[17].author.id | https://openalex.org/A5053376791 |
| authorships[17].author.orcid | https://orcid.org/0000-0002-5743-3013 |
| authorships[17].author.display_name | Marco Colleoni |
| authorships[17].author_position | middle |
| authorships[17].raw_author_name | Marco Colleoni |
| authorships[17].is_corresponding | False |
| authorships[18].author.id | https://openalex.org/A5076556096 |
| authorships[18].author.orcid | https://orcid.org/0000-0001-8355-6714 |
| authorships[18].author.display_name | Catherine M. Kelly |
| authorships[18].author_position | middle |
| authorships[18].raw_author_name | Catherine M. Kelly |
| authorships[18].is_corresponding | False |
| authorships[19].author.id | https://openalex.org/A5081344507 |
| authorships[19].author.orcid | https://orcid.org/0000-0001-7733-3143 |
| authorships[19].author.display_name | Gabriella Mariani |
| authorships[19].author_position | middle |
| authorships[19].raw_author_name | Gabriella Mariani |
| authorships[19].is_corresponding | False |
| authorships[20].author.id | https://openalex.org/A5074479074 |
| authorships[20].author.orcid | https://orcid.org/0000-0002-9546-5841 |
| authorships[20].author.display_name | Lucia Del Mastro |
| authorships[20].author_position | middle |
| authorships[20].raw_author_name | Lucia Del Mastro |
| authorships[20].is_corresponding | False |
| authorships[21].author.id | https://openalex.org/A5107490983 |
| authorships[21].author.orcid | |
| authorships[21].author.display_name | Olivia Blasi |
| authorships[21].author_position | middle |
| authorships[21].raw_author_name | Olivia Blasi |
| authorships[21].is_corresponding | False |
| authorships[22].author.id | https://openalex.org/A5040640445 |
| authorships[22].author.orcid | https://orcid.org/0000-0001-5239-0918 |
| authorships[22].author.display_name | Maurizio Callari |
| authorships[22].author_position | middle |
| authorships[22].raw_author_name | Maurizio Callari |
| authorships[22].is_corresponding | False |
| authorships[23].author.id | https://openalex.org/A5021113979 |
| authorships[23].author.orcid | https://orcid.org/0000-0001-9632-6686 |
| authorships[23].author.display_name | Lajos Pusztai |
| authorships[23].author_position | middle |
| authorships[23].raw_author_name | Lajos Pusztai |
| authorships[23].is_corresponding | False |
| authorships[24].author.id | https://openalex.org/A5061761089 |
| authorships[24].author.orcid | https://orcid.org/0000-0003-3590-7916 |
| authorships[24].author.display_name | Pinuccia Valagussa |
| authorships[24].author_position | middle |
| authorships[24].raw_author_name | Pinuccia Valagussa |
| authorships[24].is_corresponding | False |
| authorships[25].author.id | https://openalex.org/A5088697304 |
| authorships[25].author.orcid | https://orcid.org/0000-0003-1882-7068 |
| authorships[25].author.display_name | Giuseppe Viale |
| authorships[25].author_position | middle |
| authorships[25].raw_author_name | Giuseppe Viale |
| authorships[25].is_corresponding | False |
| authorships[26].author.id | https://openalex.org/A5058537459 |
| authorships[26].author.orcid | https://orcid.org/0000-0002-2372-9625 |
| authorships[26].author.display_name | Luca Gianni |
| authorships[26].author_position | middle |
| authorships[26].raw_author_name | Luca Gianni |
| authorships[26].is_corresponding | False |
| authorships[27].author.id | https://openalex.org/A5050476736 |
| authorships[27].author.orcid | https://orcid.org/0000-0002-6790-6267 |
| authorships[27].author.display_name | Giampaolo Bianchini |
| authorships[27].author_position | last |
| authorships[27].raw_author_name | Giampaolo Bianchini |
| authorships[27].is_corresponding | False |
| has_content.pdf | True |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S1_from_The_Immune-Related_27-Gene_Signature_DetermaIO_Predicts_Response_to_Neoadjuvant_Atezolizumab_plus_Chemotherapy_in_Triple-Negative_Breast_Cancer/27434278/1/files/50134564.pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Supplementary Figure S1 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10158 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9987999796867371 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2730 |
| primary_topic.subfield.display_name | Oncology |
| primary_topic.display_name | Cancer Immunotherapy and Biomarkers |
| related_works | https://openalex.org/W4248636606, https://openalex.org/W3024972238, https://openalex.org/W4401573389, https://openalex.org/W4388045576, https://openalex.org/W2186633408, https://openalex.org/W2788599721, https://openalex.org/W2706973099, https://openalex.org/W2903279629, https://openalex.org/W3142396241, https://openalex.org/W4402558537 |
| cited_by_count | 0 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1158/1078-0432.27434278 |
| best_oa_location.is_oa | True |
| best_oa_location.source | |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S1_from_The_Immune-Related_27-Gene_Signature_DetermaIO_Predicts_Response_to_Neoadjuvant_Atezolizumab_plus_Chemotherapy_in_Triple-Negative_Breast_Cancer/27434278/1/files/50134564.pdf |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.1158/1078-0432.27434278 |
| primary_location.id | doi:10.1158/1078-0432.27434278 |
| primary_location.is_oa | True |
| primary_location.source | |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S1_from_The_Immune-Related_27-Gene_Signature_DetermaIO_Predicts_Response_to_Neoadjuvant_Atezolizumab_plus_Chemotherapy_in_Triple-Negative_Breast_Cancer/27434278/1/files/50134564.pdf |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.1158/1078-0432.27434278 |
| publication_date | 2024-11-01 |
| publication_year | 2024 |
| referenced_works_count | 0 |
| abstract_inverted_index.1. | 2 |
| abstract_inverted_index.40 | 42 |
| abstract_inverted_index.by | 20 |
| abstract_inverted_index.of | 5, 13, 16, 30, 41 |
| abstract_inverted_index.The | 33 |
| abstract_inverted_index.and | 22 |
| abstract_inverted_index.arm | 21 |
| abstract_inverted_index.the | 11, 27, 39 |
| abstract_inverted_index.Dots | 25 |
| abstract_inverted_index.grey | 35 |
| abstract_inverted_index.line | 37 |
| abstract_inverted_index.read | 14, 28 |
| abstract_inverted_index.data. | 8 |
| abstract_inverted_index.depth | 15, 29 |
| abstract_inverted_index.Figure | 1 |
| abstract_inverted_index.coding | 18 |
| abstract_inverted_index.dashed | 36 |
| abstract_inverted_index.single | 31 |
| abstract_inverted_index.NeoTRIP | 6 |
| abstract_inverted_index.Quality | 3 |
| abstract_inverted_index.RNA-Seq | 7 |
| abstract_inverted_index.control | 4 |
| abstract_inverted_index.cut-off | 40 |
| abstract_inverted_index.million | 43 |
| abstract_inverted_index.regions | 19 |
| abstract_inverted_index.showing | 10 |
| abstract_inverted_index.status. | 24 |
| abstract_inverted_index.Boxplots | 9 |
| abstract_inverted_index.response | 23 |
| abstract_inverted_index.samples. | 32 |
| abstract_inverted_index.targeted | 17 |
| abstract_inverted_index.represent | 26 |
| abstract_inverted_index.horizontal | 34 |
| abstract_inverted_index.paired-end | 44 |
| abstract_inverted_index.represents | 38 |
| abstract_inverted_index.distribution | 12 |
| abstract_inverted_index.reads.</p> | 45 |
| abstract_inverted_index.<p>Supplementary | 0 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 28 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.7900000214576721 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.38101888 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |